References
- El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology127(5 Suppl. 1), S27–S34 (2004).
- Alkhouri N, Zein NN. Protease inhibitors: silver bullets for chronic hepatitis C infection? Cleve. Clin. J. Med.79(3), 213–222 (2012).
- Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology49(4), 1335–1374 (2009).
- El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology36(5 Suppl. 1), S74–S83 (2002).
- Fried MW, Afdhal NH, Wahed AS et al. A randomized, placebo-controlled trial of oral silymarin (milk thistle) for chronic hepatitis c: final results of the SYNCH multicenter study. Presented at: 62nd American Association for the Study of Liver Diseases Annual Meeting. San Francisco, CA, USA, 4–8 November 2011 (Abstract 228).
- Bourliere M, Khaloun A, Wartelle-Bladou C et al. Future treatment of patients with HCV cirrhosis. Liver Int.32(Suppl. 1), 113–119 (2012).
- Everson GT, Hoefs JC, Seeff LB et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology44(6), 1675–1684 (2006).
- Gonzalez OFV, Raychaudhuri S, Loo R et al. The heat shock protein inhibitor quercetin attenuates hepatitis C virus production. Hepatology50(6), 1756–1764 (2009).
- Sullivan CS, Pipas JM. The virus-chaperone connection. Virology287(1), 1–8 (2001).
- French SW, Gonzalez O, Maloney E et al. The effects of bioflavonoids on hepatitis C viral infection and their therapeutic potential. FASEB J.25(1 Meeting Abstracts) (2011) (Abstract 366.310).
- Khachatoorian R, Arumugaswami V, Ruchala P et al. A cell-permeable hairpin peptide inhibits hepatitis C viral nonstructural protein 5A-mediated translation and virus production. Hepatology doi:10.1002/hep.25533 (2011) (Epub ahead of print).
- Jakubowicz-Gil J, Pawlikowska-Pawlega B, Piersiak T, Pawelec J, Gawron A. Quercetin suppresses heat shock-induced nuclear translocation of Hsp72. Folia Histochem. Cytobiol.43(3), 123–128 (2005).
- Nieman D. Quercetins bioactive effects in human atheletes. Curr. Topics Nutraceut. Res.8(1), 33–44 (2010).
- Nahmias Y, Goldwasser J, Casali M et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology47(5), 1437–1445 (2008).
- Bischoff SC. Quercetin: potentials in the prevention and therapy of disease. Curr. Opin. Clin. Nut. Metab. Care11(6), 733–740 (2008).
- Brown JP. A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutat. Res.75(3), 243–277 (1980).
- Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol.45(11), 2179–2205 (2007).
Websites
- WHO. Hepatitis C: Fact Sheet No 164. www.who.int/mediacentre/factsheets/fs164/en/index.html
- CDC. Hepatitis C overview and statistics. www.cdc.gov/hepatitis/HCV/HCVfaq.htm#section1